

# Daisy Huynh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4613858/publications.pdf>

Version: 2024-02-01

33  
papers

1,414  
citations

516215

16  
h-index

525886

27  
g-index

33  
all docs

33  
docs citations

33  
times ranked

2855  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020, 11, 2996.	5.8	98
2	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. <i>Nature Cancer</i> , 2020, 1, 493-506.	5.7	209
3	Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1454-1463.	1.9	70
4	Platelets Enhance Multiple Myeloma Progression via IL-1 $\beta$ Upregulation. <i>Clinical Cancer Research</i> , 2018, 24, 2430-2439.	3.2	44
5	Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. <i>PLoS ONE</i> , 2018, 13, e0204589.	1.1	17
6	Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. <i>Blood</i> , 2018, 132, 2608-2612.	0.6	29
7	Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. <i>Blood Advances</i> , 2018, 2, 1272-1276.	2.5	9
8	Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. <i>Leukemia</i> , 2018, 32, 1739-1750.	3.3	34
9	Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. <i>Journal of Clinical Investigation</i> , 2018, 128, 2487-2499.	3.9	80
10	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , 2018, 132, 749-749.	0.6	6
11	Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma. <i>Blood</i> , 2018, 132, 2603-2603.	0.6	1
12	Deciphering Clonal Evolution and Dissemination of Multiple Myeloma Cells In Vivo. <i>Blood</i> , 2018, 132, 55-55.	0.6	0
13	Dissecting the Epigenetic Landscape of Smoldering, Newly Diagnosed and Relapsed Multiple Myeloma Revealed IRAK3 As a Marker of Disease Progression. <i>Blood</i> , 2018, 132, 3896-3896.	0.6	1
14	Prognostic role of circulating exosomal miRNAs in multiple myeloma. <i>Blood</i> , 2017, 129, 2429-2436.	0.6	214
15	A novel in vivo model for studying conditional dual loss of BLIMP1 and p53 in B cells, leading to tumor transformation. <i>American Journal of Hematology</i> , 2017, 92, E138-E145.	2.0	3
16	Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	53
17	The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. <i>Cell Reports</i> , 2017, 19, 218-224.	2.9	92
18	In Vivo Genome-Wide Crispr Library Screen in a Xenograft Mouse Model of Tumor Growth and Metastasis of Multiple Myeloma. <i>Blood</i> , 2016, 128, 1137-1137.	0.6	2

#	ARTICLE	IF	CITATIONS
19	Whole-Exome Sequencing and Targeted Deep Sequencing of cfDNA Enables a Comprehensive Mutational Profiling of Multiple Myeloma. <i>Blood</i> , 2016, 128, 197-197.	0.6	8
20	Whole Exome Sequencing and Targeted Sequencing Reveal the Heterogeneity of Genomic Evolution and Mutational Profile in Smoldering Multiple Myeloma. <i>Blood</i> , 2016, 128, 237-237.	0.6	0
21	Microrna-138 Regulates Osteogenic Differentiation and Its Inhibition Presents a Novel Therapeutic Line to Prevent Bone Lytic Lesions in Multiple Myeloma. <i>Blood</i> , 2016, 128, 4483-4483.	0.6	0
22	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. <i>Cell Reports</i> , 2015, 12, 622-635.	2.9	123
23	The cancer glycome: Carbohydrates as mediators of metastasis. <i>Blood Reviews</i> , 2015, 29, 269-279.	2.8	91
24	Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma. <i>Blood</i> , 2015, 126, 23-23.	0.6	37
25	Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma. <i>Blood</i> , 2015, 126, 502-502.	0.6	4
26	MYC Regulation Via the LIN28B/Let-7 Axis in Multiple Myeloma. <i>Blood</i> , 2015, 126, 1755-1755.	0.6	0
27	Circulating Exosomal microRNAs Are Prognostic Markers in Multiple Myeloma. <i>Blood</i> , 2015, 126, 1770-1770.	0.6	4
28	Platelets/Megakaryocytes Are Critical Regulators of Tumor Progression in Multiple Myeloma. <i>Blood</i> , 2015, 126, 1793-1793.	0.6	1
29	Regulation of microRNAs in cancer metastasis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 255-265.	3.3	132
30	Pyk2 promotes tumor progression in multiple myeloma. <i>Blood</i> , 2014, 124, 2675-2686.	0.6	51
31	Novel CXCR4-Targeted Therapy to Inhibit Multiple Myeloma Bone Dissemination. <i>Blood</i> , 2014, 124, 4709-4709.	0.6	1
32	Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 2056-2056.	0.6	0
33	Metabolomic Profiling Identifies Mechanisms Regulating Hypoxia-Induced Drug Resistance In Multiple Myeloma. <i>Blood</i> , 2013, 122, 121-121.	0.6	0